TLR2 and COVID-19: Moreover, in a SARS-CoV-2 ferret infection model, prophylactic intranasal administration of the TLR2/6 agonist INNA-051 effectively reduced levels of viral RNA in the nose and throat, supporting the clinical development of a therapy based on prophylactic TLR2/6 innate immune activation to reduce SARS-CoV-2 transmission and providing protection against COVID-19 [135].